Company Overview and News

0
Hong Kong stocks end lower after Trump says he’s ‘not pleased’ with progress on US-China trade talks

2018-05-23 scmp
Hong Kong and mainland stocks fell on Wednesday after US President Donald Trump said he was “not pleased” with the progress of US-China trade talks, which had fuelled market optimism in recent days.
1898 HUNGF HNP 0902 1088

7
Bear of the Day: Consol Coal (CCR)

2018-03-28 zacks
The coal stocks had a stretch where they came out from underground and had their day in the sun. Lately, that hasn’t been the case as these stocks have come under pressure. Today’s Bear of the Day is a stock in that industry which has struggled to produce earnings growth. I’m talking about Zacks Rank #5 (Strong Sell) CONSOL Coal Resources (CCR - Free Report) .
1898 CCR TXN CNTE

6
Here's Why You Should Hold Natural Resource Partners Now

2018-03-27 zacks
Shares of Natural Resource Partners LP (NRP - Free Report) have outperformed the Coal industry in the last three months. The stock has returned 18.7% compared with the industry’s gain of 1.2 %. Natural Resource Partners carries a Zacks Rank #3 (Hold).
1898 FTI.WI NRP FMC CNTE SXC

0
Shenhua Profit Rises to 5-Year High as China Curbs Boost Coal - Bloomberg

2018-03-25 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
1898 YACAF YZC K3GD 1171 YZCHF YAL 1088

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...